全球神经保护市场规模、份额、趋势和成长分析报告（2026-2034年）

预计神经保护市场将从 2025 年的 434.6 亿美元成长到 2034 年的 857.2 亿美元，2026 年至 2034 年的复合年增长率为 7.84%。

由于阿兹海默症、帕金森氏症和中风併发症等神经退化性疾病的发生率不断上升，全球神经保护市场日益受到关注。神经科学研究投入的增加以及创新神经保护药物临床试验的扩展正在推动市场成长。製药公司正致力于研发治疗方法。

成长要素包括全球人口老化、早期诊断意识的提高以及基于生物标记的检测技术的进步。政府对神经系统疾病研究和开发的资助以及支持性的法规结构正在加速药物研发。此外，生技公司与学术机构之间的合作也正在加速神经保护疗法的创新。

未来几年，个人化医疗和基因疗法有望彻底改变神经保护领域。包括干细胞疗法和神经营养因子在内的新治疗方法有望创造新的收入来源。新兴国家医疗基础设施的扩建以及患者获得先进治疗的便利性提高，将进一步增强市场的长期前景。

目录

第一章：引言

第二章执行摘要

第三章 市场变数、趋势与框架

• 市场谱系展望
• 渗透率和成长前景分析
• 价值链分析
• 法律规范
  • 标准与合规性
  • 监管影响分析
• 市场动态
  • 市场驱动因素
  • 市场限制因素
  • 市场机会
  • 市场挑战
• 波特五力分析
• PESTLE分析

第四章：全球神经保护市场：依药物类型划分

• 市场分析、洞察与预测
• 自由基清除剂（抗氧化剂）
• 麸胺酸拮抗剂（抗兴奋性毒性药物）
• 细胞凋亡抑制剂
• 抗发炎药
• 神经营养因子（NTFs）
• 金属离子螯合剂
• 兴奋剂
• 其他的

第五章 全球神经保护市场：按应用划分

• 市场分析、洞察与预测
• 预防
• 治疗

第六章 全球神经保护市场：依地区划分

• 区域分析
• 北美市场分析、洞察与预测
  • 我们
  • 加拿大
  • 墨西哥
• 欧洲市场分析、洞察与预测
  • 英国
  • 法国
  • 德国
  • 义大利
  • 俄罗斯
  • 其他欧洲国家
• 亚太市场分析、洞察与预测
  • 印度
  • 日本
  • 韩国
  • 澳洲
  • 东南亚
  • 其他亚太国家
• 拉丁美洲市场分析、洞察与预测
  • 巴西
  • 阿根廷
  • 秘鲁
  • 智利
  • 其他拉丁美洲国家
• 中东和非洲市场分析、洞察与预测
  • 沙乌地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中东和非洲国家

第七章 竞争情势

• 最新趋势
• 公司分类
• 供应链和销售管道合作伙伴（根据现有资讯）
• 市场占有率和市场定位分析（基于现有资讯）
• 供应商情况（基于现有资讯）
• 策略规划

第八章：公司简介

• 主要公司的市占率分析
• 公司简介
  • Eli Lilly And Company
  • AbbVie Inc
  • Dr. Reddy'S Laboratories Ltd
  • Teva Pharmaceutical Industries Ltd
  • Novartis AG
  • AstraZeneca Plc
  • Astrocyte Pharmaceuticals Inc
  • F. Hoffmann-La Roche AG
  • Biogen Inc
  • Pfizer Inc
  • Johnson & Johnson
  • Merck & Co. Inc
  • Gilead Sciences
  • Amgen Inc

The Neuroprotection Market size is expected to reach USD 85.72 Billion in 2034 from USD 43.46 Billion (2025) growing at a CAGR of 7.84% during 2026-2034.

The Global Neuroprotection Market is gaining traction due to rising prevalence of neurodegenerative disorders such as Alzheimer's disease, Parkinson's disease, and stroke-related complications. Increasing research investments in neuroscience and growing clinical trials for innovative neuroprotective agents are driving market expansion. Pharmaceutical companies are focusing on therapies that prevent neuronal damage and improve long-term cognitive outcomes.

Growth drivers include the aging global population, heightened awareness about early diagnosis, and advancements in biomarker-based detection techniques. Government funding for neurological research and supportive regulatory frameworks are encouraging drug development. Additionally, partnerships between biotech firms and academic institutions are accelerating innovation in neuroprotective therapies.

In the coming years, personalized medicine and gene-based therapies are expected to transform the neuroprotection landscape. Emerging treatment modalities, including stem cell therapy and neurotrophic factors, will likely create new revenue streams. Expanding healthcare infrastructure in emerging economies and improved patient access to advanced therapies will further strengthen long-term market prospects.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Drug Type

• Free Radical Trapping Agents (Antioxidants)
• Glutamate Antagonists (Anti-excitotoxic Agents)
• Apoptosis Inhibitors
• Anti-inflammatory Agents
• Neurotrophic Factors (NTFs)
• Metal Ion Chelators
• Stimulants
• Others

By Application

• Prevention
• Treatment

COMPANIES PROFILED

• Daiichi Sankyo Company, , Eli Lilly and Company, AbbVie Inc, Dr Reddys Laboratories Ltd, Teva Pharmaceutical Industries Ltd, Novartis AG, AstraZeneca plc, Astrocyte Pharmaceuticals Inc, F HoffmannLa Roche AG, Biogen Inc, Pfizer Inc, Johnson Johnson, Merck Co Inc, Gilead Sciences, Amgen Inc
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL NEUROPROTECTION MARKET: BY DRUG TYPE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Drug Type
• 4.2. Free Radical Trapping Agents (Antioxidants) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Glutamate Antagonists (Anti-excitotoxic Agents) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Apoptosis Inhibitors Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Anti-inflammatory Agents Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.6. Neurotrophic Factors (NTFs) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.7. Metal Ion Chelators Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.8. Stimulants Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.9. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL NEUROPROTECTION MARKET: BY APPLICATION 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Application
• 5.2. Prevention Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Treatment Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL NEUROPROTECTION MARKET: BY REGION 2022-2034(USD MN)

• 6.1. Regional Outlook
• 6.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.2.1 By Drug Type
  • 6.2.2 By Application
  • 6.2.3 United States
  • 6.2.4 Canada
  • 6.2.5 Mexico
• 6.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.3.1 By Drug Type
  • 6.3.2 By Application
  • 6.3.3 United Kingdom
  • 6.3.4 France
  • 6.3.5 Germany
  • 6.3.6 Italy
  • 6.3.7 Russia
  • 6.3.8 Rest Of Europe
• 6.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.4.1 By Drug Type
  • 6.4.2 By Application
  • 6.4.3 India
  • 6.4.4 Japan
  • 6.4.5 South Korea
  • 6.4.6 Australia
  • 6.4.7 South East Asia
  • 6.4.8 Rest Of Asia Pacific
• 6.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.5.1 By Drug Type
  • 6.5.2 By Application
  • 6.5.3 Brazil
  • 6.5.4 Argentina
  • 6.5.5 Peru
  • 6.5.6 Chile
  • 6.5.7 South East Asia
  • 6.5.8 Rest of Latin America
• 6.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.6.1 By Drug Type
  • 6.6.2 By Application
  • 6.6.3 Saudi Arabia
  • 6.6.4 UAE
  • 6.6.5 Israel
  • 6.6.6 South Africa
  • 6.6.7 Rest of the Middle East And Africa

Chapter 7. COMPETITIVE LANDSCAPE

• 7.1. Recent Developments
• 7.2. Company Categorization
• 7.3. Supply Chain & Channel Partners (based on availability)
• 7.4. Market Share & Positioning Analysis (based on availability)
• 7.5. Vendor Landscape (based on availability)
• 7.6. Strategy Mapping

Chapter 8. COMPANY PROFILES OF GLOBAL NEUROPROTECTION INDUSTRY

• 8.1. Top Companies Market Share Analysis
• 8.2. Company Profiles
  • 8.2.1 Eli Lilly And Company
  • 8.2.2 AbbVie Inc
  • 8.2.3 Dr. Reddy'S Laboratories Ltd
  • 8.2.4 Teva Pharmaceutical Industries Ltd
  • 8.2.5 Novartis AG
  • 8.2.6 AstraZeneca Plc
  • 8.2.7 Astrocyte Pharmaceuticals Inc
  • 8.2.8 F. Hoffmann-La Roche AG
  • 8.2.9 Biogen Inc
  • 8.2.10 Pfizer Inc
  • 8.2.11 Johnson & Johnson
  • 8.2.12 Merck & Co. Inc
  • 8.2.13 Gilead Sciences
  • 8.2.14 Amgen Inc